Veraxa Biotech AG
corporate_fare Company Profile
Veraxa Biotech AG (NASDAQ:VRXA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for VRXA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for VRXA spans 6-K, 424B5, F-1, 20-F.
Recent high-impact activity:
- Veraxa Auditor BDO Resigns; KPMG Proposed at 10 December EGM
- Veraxa Biotech Reports First In Vivo Proof-of-Concept for BiTAC-ADC Platform
- Veraxa Registers 25M Shares for Lincoln Park Equity Line Resale
- Veraxa Biotech Files F-1 to Register 140M+ Shares for Resale and Warrant Exercise, Unlocking Massive Overhang
- Veraxa Biotech Registers 25M Shares for Lincoln Park Resale Under $50M Equity Line
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 91,222 shares in VRXA as of the October 30, 2026 settlement, a 15.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 29.5% of VRXA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for VRXA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-10.
Equity Line Registration Effective · Dilution Overhang
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
VRXA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.